Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReckitt Regulatory News (RKT)

Share Price Information for Reckitt (RKT)

Share Price is delayed by 15 minutes
Get Live Data
4,569.00    29.00 (0.64%)
Bid:
4,569.00
Ask:
4,571.00
Spread: 2.00 (0.044%)
Market Cap: £29.05b
RKT Live PriceLast checked at - London Stock Exchange

Intraday Reckitt Share Chart

Directorate Change

27 Nov 2024 07:00

RNS Number : 7467N
Reckitt Benckiser Group PLC
27 November 2024
 

 

RECKITT BENCKISER GROUP PLC

DIRECTORATE CHANGE

 

Reckitt announces the appointment of

Mahesh Madhavan and Stefan Oschmann as Non-Executive Directors

 

Reckitt Benckiser Group plc (the "Company" or "Reckitt") today announces the appointment of Mahesh Madhavan, current CEO of Bacardi and Stefan Oschmann, former CEO of Merck KGaA, to the Board as Non-Executive Directors, effective 1 January 2025.

 

Mahesh is CEO of Bacardi Ltd having joined in 1997 and held a number of regional leadership roles before being promoted to CEO in 2017. Since becoming CEO he has led a successful transformation of the business, providing stability and a clear strategy for success to the organisation. Previously, Mahesh held various roles at International Distillers & Vintners, FCB Ulka Advertising and Wipro Consumer products.

 

Mahesh is currently a Non-Executive Director of Capri Holdings.

 

Mahesh will join the Remuneration Committee from February 2025.

 

Stefan Oschmann is the former CEO and Chair of Merck KGaA which he joined in 2011 as a member of the Executive Board and CEO of Merck Biopharma and held a number of senior leadership roles within the healthcare business before becoming CEO and Chair of Merck between 2016 and 2021. Prior to that Stefan spent 30 years at Merck & Co in various leadership roles. Stefan brings strong transformational experience in science, healthcare and technology.

 

Stefan is currently a Non-Executive Director at Stamm, European Healthcare Acquisition & Growth, Springer Nature and is Chair of AiCuris Anti-Infective Cures.

 

Stefan will join the Compliance Committee from February 2025.

 

Commenting on the appointment, Sir Jeremy Darroch, Chair of the Board said:

 

"I am delighted that Mahesh and Stefan have agreed to join the Reckitt Board. They are both outstanding leaders, with many years' experience as CEO's of large global businesses. We welcome the value and expertise both will bring to the Board."

 

The Company confirms that there is no further information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to the appointments.

 

 

Contact Details:

 

Catheryn O'Rourke +44 (0) 1753 217 800

General Counsel & Company Secretary

 

Nick Ashworth +44 (0) 7408 812350

Investor Relations

 

 

About Reckitt:

 

Reckitt* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege.

 

Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Calgon, Cillit Bang, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more.

 

Every day, more than 20 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always.

 

We are a diverse global team of c. 40,000 colleagues. We draw on our collective energy to meet our ambitions of purpose-led brands, a healthier planet and a fairer society. Find out more, or get in touch with us at www.reckitt.com

 

* Reckitt is the trading name of the Reckitt Benckiser group of companies

 

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPPGQAGUPCGQQ
Date   Source Headline
10th Jun 20267:00 amRNSTransaction in Own Shares
9th Jun 20267:00 amRNSTransaction in Own Shares
8th Jun 20262:30 pmRNSEMTN Programme: Publication of Final Terms
8th Jun 20267:00 amRNSTransaction in Own Shares
5th Jun 20267:00 amRNSTransaction in Own Shares
4th Jun 20267:00 amRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSTransaction in Own Shares
2nd Jun 20261:26 pmRNSDirector/PDMR Shareholding
2nd Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20265:32 pmRNSDirector/PDMR Shareholding
1st Jun 20262:05 pmRNSTotal Voting Rights
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20267:00 amRNSTransaction in Own Shares
28th May 20267:00 amRNSTransaction in Own Shares
27th May 20267:00 amRNSTransaction in Own Shares
26th May 20265:42 pmRNSEMTN Programme: Publication of Final Terms
26th May 20267:00 amRNSTransaction in Own Shares
22nd May 20267:00 amRNSTransaction in Own Shares
21st May 20264:44 pmRNSResult of AGM
21st May 20267:00 amRNSTransaction in Own Shares
20th May 20267:00 amRNSTransaction in Own Shares
19th May 20267:00 amRNSTransaction in Own Shares
18th May 20267:00 amRNSTransaction in Own Shares
15th May 202610:18 amRNSPublication of Supplementary Prospectus
15th May 20267:00 amRNSTransaction in Own Shares
14th May 20267:00 amRNS‘RECKITT FOCUS ON’ INVESTOR SEMINAR
14th May 20267:00 amRNSTransaction in Own Shares
13th May 20267:00 amRNSTransaction in Own Shares
12th May 20267:00 amRNSTransaction in Own Shares
11th May 20267:00 amRNSTransaction in Own Shares
8th May 20267:00 amRNSTransaction in Own Shares
7th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSTransaction in Own Shares
5th May 20267:00 amRNSTransaction in Own Shares
1st May 20262:51 pmRNSTotal Voting Rights
1st May 20267:00 amRNSTransaction in Own Shares
30th Apr 20267:00 amRNSTransaction in Own Shares
29th Apr 20263:30 pmRNSDirector/PDMR Shareholding
29th Apr 20267:00 amRNSTransaction in Own Shares
28th Apr 20267:00 amRNSTransaction in Own Shares
27th Apr 20267:00 amRNSTransaction in Own Shares
24th Apr 20267:00 amRNSTransaction in Own Shares
23rd Apr 20263:00 pmRNSDirector Declaration
23rd Apr 20267:00 amRNSTransaction in Own Shares
22nd Apr 20267:00 amRNSQ1 RESULTS 2026
22nd Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20267:00 amRNSTransaction in Own Shares
17th Apr 20267:00 amRNSTransaction in Own Shares
16th Apr 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.